Market Overview

Seattle Genetics Will Get Undisclosed Milestone Payments

Related SGEN
Kinder Morgan, Seattle Genetics And Others Insiders Have Been Buying
American Express, General Electric And Other Stocks Insiders Have Been Buying

Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that it will receive undisclosed milestone payments under its antibody-drug conjugate (ADC) collaboration with Genentech, a member of the Roche Group (SWX:RO) (SWX:ROG) (OTC: RHHBY). The milestones were triggered by Genentech's advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 (DCDT2980S, RG7593) and DCDS4501A (RG7596) each in combination with Rituxan® (rituximab) in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.

Posted-In: News FDA


Related Articles (SGEN + RHHBY)

Around the Web, We're Loving...